NASDAQ:KOD Kodiak Sciences Q4 2024 Earnings Results & Report $88.12 +7.03 (+8.67%) Closing price 04:00 PM EasternExtended Trading$88.25 +0.13 (+0.15%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kodiak Sciences beat analyst earnings expectations in its Q4 2024 results, released March 27, 2025. The company reported EPS of -$0.84 versus the -$0.90 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 27, 2025TimeBefore Market OpensConference Call10:30 AM ET Kodiak Sciences EPS ResultsActual EPS-$0.84Consensus EPS -$0.90Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersKodiak Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsKodiak Sciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Kodiak Sciences Q4 2024 Earnings FAQ Did Kodiak Sciences beat earnings estimates for Q4 2024? Kodiak Sciences (NASDAQ:KOD) reported earnings of -$0.84 per share for Q4 2024, beating the consensus estimate of -$0.90. The report was announced on Thursday, March 27, 2025. When is Kodiak Sciences' next earnings date? Kodiak Sciences' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Kodiak Sciences on the company's earnings history page. Kodiak Sciences Earnings HeadlinesHC Wainwright Comments on Kodiak Sciences FY2030 EarningsOctober 15 at 2:44 AM | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Kodiak Sciences (KOD), Newron Pharmaceuticals SpA (OtherNWPHF) and Illumina (ILMN)October 13 at 12:14 PM | theglobeandmail.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - SlideshowOctober 10, 2026 | seekingalpha.comKodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial NewsOctober 9, 2026 | finance.yahoo.comKodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data UpdateOctober 8, 2026 | finance.yahoo.comSee More Kodiak Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email. Email Address About Kodiak SciencesKodiak Sciences (NASDAQ:KOD) (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye. Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Its principal investigational product, KSI-301, is an anti-VEGF-A therapy designed for longer-lasting activity than conventional treatments. Kodiak has also researched KSI-501, a potential dual-action therapy intended to target both VEGF-A and inflammatory pathways implicated in retinal disease. Founded in 2009, Kodiak has conducted clinical development activities in the United States and other international markets. The company is led by Victor Perlroth, M.D., who co-founded Kodiak and has served as its chief executive officer. Kodiak’s development programs remain focused on addressing the treatment burden associated with frequent intraocular injections for patients with retinal disorders.View Kodiak Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
